CSIMarket
Company Name or Ticker Symbol
Search for other Categories
 
 
 


Neurocrine Biosciences Inc  (NBIX)
Other Ticker:  
 
    Sector  Healthcare    Industry Biotechnology & Drugs
 
   Industry Biotechnology & Drugs
   Sector  Healthcare
 

NBIX's Revenue Growth by Quarter and Year

Neurocrine Biosciences Inc's Revenue results by quarter and year




NBIX Revenue (in millions $) FY 2018 FY 2017 FY 2016 FY 2015
IV Quarter December - 94.52 - -
III Quarter September - 60.77 - -
II Quarter June 96.91 6.34 - -
I Quarter March 71.09 - 15.00 19.77
FY   168.00 161.63 15.00 19.77



NBIX Revenue second quarter 2018 Y/Y Growth Comment
Neurocrine Biosciences Inc achieved in the second quarter, above Company average Revenue surge of 1428.47% year on year, to $ 96.91 millions.

Looking into second quarter results within Biotechnology & Drugs industry 4 other companies have achieved higher Revenue growth. While Neurocrine Biosciences Inc' s Revenue doubling of 1428.47% ranks overall at the positon no. 38 in the second quarter.




NBIX Revenue ( Y/Y Growth %) 2018
2017 2016 2015
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June 1428.47 % - - -
I Quarter March - - -24.13 % -
FY   - 977.53 % -24.13 % -

Financial Statements
Neurocrine Biosciences Inc's second quarter 2018 Revenue $ 96.91 millions NBIX's Income Statement
Neurocrine Biosciences Inc's second quarter 2017 Revenue $ 6.34 millions Quarterly NBIX's Income Statement
New: More NBIX's historic Revenue Growth >>


NBIX Revenue (Quarter on Quarter Growth %)

2018
2017 2016 2015
IV Quarter December - 55.54 % - -
III Quarter September - 858.52 % - -
II Quarter June 36.31 % - - -
I Quarter March -24.79 % - - -
FY (Year on Year)   - 977.53 % -24.13 % -




Revenue second quarter 2018 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #5
Healthcare Sector #18
Overall #38
Revenue Y/Y Growth Statistics
High Average Low
38.92 % -6.87 % -52.66 %
(Jun 30 2018)   (Dec. 30, 2013)

Revenue by Quarter for the Fiscal Years 2015, 2016, 2017, 2018
You need to upgrade your Flash Player

Neurocrine Biosciences Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #16
Healthcare Sector #56
Overall #170
Revenue Q/Q Growth Statistics
High Average Low
859.34 % 84.31 % -100 %
(Sep 30 2017)  


NBIX's II. Quarter Q/Q Revenue Comment
Neurocrine Biosciences Inc achieved in the II. Quarter 2018 below company average Revenue jump of 36.31% quarter on quarter, to $ 96.91 millions.

Albeit the II. Quarter 2018 NBIX's performance was below the ordinary , that has been still promising news, as the II. Quarter expension, outshines the % Revenue growth in the II. Quarter a year ago

Within Biotechnology & Drugs industry 15 other companies have achieved higher Revenue quarter on quarter growth. While Neurocrine Biosciences Inc's Revenue growth quarter on quarter, overall rank is 170.


Neurocrine Biosciences Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2018)
12 Months Ending
(Mar 31 2018)
12 Months Ending
(Dec 31 2017)
12 Months Ending
(Sep 30 2017)
12 Months Ending
(Jun 30 2017)
Cumulative Revenue 12 Months Ending $ 323.28 $ 232.71 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) 38.92 % - - - -
Seq. Revenue Growth (TTM) Overall Ranking # 105 # 0 # 0 # 0 # 0




Cumulative Revenue growth Comment
Neurocrine Biosciences Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 1428.47% year on year, to $ 323 millions if the fiscal year would have ended in Jun 30 2018.
Neurocrine Biosciences Inc's trailing twelve months Revenue growth was higher than company's average -52.66% and higher than % growth in Mar 31 2018. And, Neurocrine Biosciences Inc realized the fastest Revenue growth, in Biotechnology & Drugs industry.
But sequential growth rate was beneth at 38.92 % from $232.71 millions achieved in twelve months ending a quarter Mar 31 2018 Zoe  Davies went on.
Still this was evidence of strength, as the typical sequential advancement stands at -6.87%.

Neurocrine Biosciences Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Q/Q Growth Statistics
High Average Low
38.92 %
-6.87 %
-52.66 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Drugs Industry #
Healthcare Sector #
Overall # 0

Revenue TTM Y/Y Growth Statistics
High Average Low
-52.66 %
-52.66 %
-52.66 %
(Dec. 30, 2013)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 12
Sector # 34
S&P 500 # 105


You need to upgrade your Flash Player




Other Revenue Growth
Biotechnology & Drugs Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NBIX's Revenue Growth Ratio versus Biotechnology & Drugs Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for NBIX's Competitors
Revenue Growth for Neurocrine Biosciences Inc's Suppliers
Revenue Growth for NBIX's Customers

You may also want to know
NBIX's Annual Growth Rates NBIX's Profitability Ratios NBIX's Asset Turnover Ratio NBIX's Dividend Growth
NBIX's Roe NBIX's Valuation Ratios NBIX's Financial Strength Ratios NBIX's Dividend Payout Ratio
NBIX's Roa NBIX's Inventory Turnover Ratio NBIX's Growth Rates NBIX's Dividend Comparisons



Companies with similar Revenue jump for the quarter ending Jun 30 2018 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2018
Viewray, Inc.  2,255.73 %$ 2,255.731 millions
Radius Health, Inc.  2,209.08 %$ 2,209.082 millions
Spark Therapeutics, Inc.  1,597.98 %$ 1,597.980 millions
Neurocrine Biosciences Inc  1,429.68 %$ 1,429.676 millions
Dynavax Technologies Corp  1,094.29 %$ 1,094.286 millions
United Cannabis Corp  1,034.34 %$ 1,034.337 millions
Macrogenics Inc  1,030.49 %$ 1,030.492 millions
Genesis Healthcare, Inc.  917.00 %$ 917.001 millions
Quest Patent Research Corp  876.64 %$ 876.639 millions
Revance Therapeutics, Inc.  814.67 %$ 814.667 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

SMBC's Profile

Stock Price

SMBC's Financials

Business Description

Fundamentals

Charts & Quotes

SMBC's News

Suppliers

SMBC's Competitors

Customers & Markets

Economic Indicators

SMBC's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Expectations

Management Effectivness

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us



CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2018 CSIMarket, Inc. All rights reserved. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)
Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071